These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 21875342

  • 1. Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.
    Park SH, Choi SM, Lee DG, Kim J, Choi JH, Kim SH, Kwon JC, Yoo JH.
    Microb Drug Resist; 2011 Dec; 17(4):537-44. PubMed ID: 21875342
    [Abstract] [Full Text] [Related]

  • 2. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, Almela M, Almirante B, Grill F, Colomina J, Giménez M, Oliver A, Horcajada JP, Navarro G, Coloma A, Pascual A, Spanish Network for Research in Infectious Diseases (REIPI).
    Clin Infect Dis; 2010 Jan 01; 50(1):40-8. PubMed ID: 19995215
    [Abstract] [Full Text] [Related]

  • 3. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, Ki HK, Son JS, Lee SS, Kim YS, Jung SI, Kim SW, Chang HH, Ryu SY, Kwon KT, Lee H, Moon C, Shin SY, Korean Network for Study of Infectious Diseases (KONSID).
    Int J Antimicrob Agents; 2010 Sep 01; 36(3):284-7. PubMed ID: 20580534
    [Abstract] [Full Text] [Related]

  • 4. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli.
    Hsieh CJ, Shen YH, Hwang KP.
    J Microbiol Immunol Infect; 2010 Jun 01; 43(3):240-8. PubMed ID: 21291853
    [Abstract] [Full Text] [Related]

  • 5. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, Song JH.
    Scand J Infect Dis; 2013 Jul 01; 45(7):519-25. PubMed ID: 23509913
    [Abstract] [Full Text] [Related]

  • 6. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
    Ferrández O, Grau S, Saballs P, Luque S, Terradas R, Salas E.
    Rev Clin Esp; 2011 Mar 01; 211(3):119-26. PubMed ID: 21371702
    [Abstract] [Full Text] [Related]

  • 7. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW.
    Antimicrob Agents Chemother; 2004 Dec 01; 48(12):4574-81. PubMed ID: 15561828
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI, Yang CS, Chen WC, Chen YC, Chang SC.
    J Microbiol Immunol Infect; 2010 Aug 01; 43(4):310-6. PubMed ID: 20688291
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N.
    J Hosp Infect; 2008 Feb 01; 68(2):108-15. PubMed ID: 18063198
    [Abstract] [Full Text] [Related]

  • 10. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for Study of Infectious Diseases.
    Ann Hematol; 2012 Jan 01; 91(1):115-21. PubMed ID: 21556875
    [Abstract] [Full Text] [Related]

  • 11. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.
    Anunnatsiri S, Towiwat P, Chaimanee P.
    Southeast Asian J Trop Med Public Health; 2012 Sep 01; 43(5):1169-77. PubMed ID: 23431823
    [Abstract] [Full Text] [Related]

  • 12. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, Holland DJ.
    Int J Infect Dis; 2012 May 01; 16(5):e371-4. PubMed ID: 22401750
    [Abstract] [Full Text] [Related]

  • 13. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.
    Am J Infect Control; 2007 Nov 01; 35(9):606-12. PubMed ID: 17980240
    [Abstract] [Full Text] [Related]

  • 14. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.
    Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD.
    J Infect; 2008 Dec 01; 57(6):441-8. PubMed ID: 18990451
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J.
    J Antimicrob Chemother; 2006 Apr 01; 57(4):780-3. PubMed ID: 16492721
    [Abstract] [Full Text] [Related]

  • 16. Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia.
    Park YS, Bae IK, Kim J, Jeong SH, Hwang SS, Seo YH, Cho YK, Lee K, Kim JM.
    Yonsei Med J; 2014 Mar 01; 55(2):467-75. PubMed ID: 24532519
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, McGowan KL, Bilker WB, Lautenbach E.
    Pediatrics; 2005 Apr 01; 115(4):942-9. PubMed ID: 15805368
    [Abstract] [Full Text] [Related]

  • 18. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.
    Rodríguez-Baño J, Alcalá J, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.
    J Antimicrob Chemother; 2009 Apr 01; 63(4):781-4. PubMed ID: 19223299
    [Abstract] [Full Text] [Related]

  • 19. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratalà J, Gudiol F.
    J Antimicrob Chemother; 2010 Feb 01; 65(2):333-41. PubMed ID: 19959544
    [Abstract] [Full Text] [Related]

  • 20. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI, Lee NY, Yan JJ, Lee HC, Ko NY, Chang CM, Wu CJ, Chen PL, Wang LR, Ko WC.
    J Microbiol Immunol Infect; 2009 Aug 01; 42(4):303-9. PubMed ID: 19949753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.